Core Viewpoint - YXTT Pharmaceutical Group Co., Ltd. has announced the use of temporarily idle funds from its 2018 convertible bond issuance for cash management, aiming to enhance the efficiency of fund utilization and generate investment returns [1][6]. Group 1: Cash Management Progress - The company has approved the use of up to RMB 325 million from the 2018 convertible bond proceeds for cash management, which includes investments in fixed-income products, time deposits, and other low-risk financial instruments [1]. - The company has signed a contract with Shanghai Pudong Development Bank for structured deposit products as part of its cash management strategy [2]. Group 2: Risk Control Measures - The company has established a series of risk control measures, including internal audits and supervision by independent directors to ensure the safety of the funds used in cash management [3][4]. - The finance department will monitor the investment products and take necessary actions if any risks to fund safety are identified [3]. Group 3: Impact on Company Performance - Engaging in low-risk cash management is expected to improve the efficiency of fund utilization and enhance overall company performance, ultimately benefiting shareholders [4]. - The company emphasizes that this cash management strategy will not interfere with the normal execution of its fundraising projects [4].
一心堂药业集团股份有限公司 关于使用部分暂时闲置2018年公开发行可转换公司债券募集资金进行现金管理的进展公告